FindTrial
Sign In

LY3502970

DRUG16 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 2HealthyHepatic InsufficiencyObeseObesityOverweightOverweight and ObesityRenal Insufficiency

Phase 1

A Study of LY3502970 in Healthy Participants
CompletedNCT03929744
Eli Lilly and CompanyHealthy
Start: 2019-06-12End: 2020-11-02Updated: 2026-07-10
A Study of LY3502970 in Participants With Type 2 Diabetes
CompletedNCT04426474
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2020-10-08End: 2021-07-12Updated: 2026-05-26
A Multiple Dose Study of LY3502970 in Healthy Participants
CompletedNCT05051566
Eli Lilly and CompanyHealthy
Start: 2021-09-16End: 2022-04-04Updated: 2026-05-29
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
CompletedNCT05086445
Eli Lilly and CompanyDiabetes Mellitus, Type 2
Start: 2021-11-12End: 2022-09-05Updated: 2026-07-16
A Multiple-Dose Study of LY3502970 in Healthy Participants
CompletedNCT05110794
Eli Lilly and CompanyHealthy
Start: 2021-11-05End: 2022-02-10Updated: 2026-05-26
A Study of LY3502970 in Healthy Overweight and Obese Participants
CompletedNCT05313802
Eli Lilly and CompanyHealthy, Obese
Start: 2022-05-26End: 2022-09-09Updated: 2026-05-26
A Study of Two Different Formulations of LY3502970 in Healthy Participants
CompletedNCT05341089
Eli Lilly and CompanyHealthy
Start: 2022-05-17End: 2022-09-01Updated: 2026-05-27
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
CompletedNCT05469126
Eli Lilly and CompanyHealthy
Start: 2022-08-01End: 2022-11-03Updated: 2026-05-27
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
CompletedNCT05573230
Eli Lilly and CompanyHealthy
Start: 2022-10-17End: 2023-01-17Updated: 2026-05-26
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
CompletedNCT05841238
Eli Lilly and CompanyHealthy, Obese
Start: 2023-04-26End: 2023-11-13Updated: 2026-07-10
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
CompletedNCT05882032
Eli Lilly and CompanyHealthy, Hepatic Insufficiency
Start: 2023-06-13End: 2024-11-18Updated: 2026-05-27
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.
CompletedNCT05936138
Eli Lilly and CompanyHealthy, Renal Insufficiency
Start: 2023-07-13End: 2024-04-11Updated: 2026-06-09
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
CompletedNCT06023095
Eli Lilly and CompanyObesity, Overweight
Start: 2023-09-21End: 2024-07-29Updated: 2026-07-17
A Phase I Study of LY3502970 in Healthy Participants
CompletedNCT06085482
Eli Lilly and CompanyHealthy
Start: 2023-10-19End: 2024-01-05Updated: 2026-05-27

Phase 2

A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
CompletedNCT05048719
Eli Lilly and CompanyType 2 Diabetes
Start: 2021-09-15End: 2022-09-30Updated: 2023-10-17
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
CompletedNCT05051579
Eli Lilly and CompanyObesity, Overweight and Obesity
Start: 2021-09-29End: 2022-11-22Updated: 2023-09-13

Related Papers

2624-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orforglipron: A Multiple Dose Titration Study in Chinese Participants with Obesity or Overweight with Weight-Related Comorbidities
Diabetes2026-06-05
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
2025-06-064 citations
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
Diabetes Therapy2024-02-2419 citations
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
2023-06-2493 citations
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
New England Journal of Medicine2023-06-23371 citations
336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
Diabetes2022-05-313 citations